Pantarhei Bioscience, the Dutch biopharmaceutical company, is pleased to announce the appointment of Yvette Zimmerman as Chief Executive Officer (CEO), with effect from January 2019. The founder of Pantarhei Herjan Coelingh Bennink speaks proudly about his successor: “Yvette is a very experienced drug developer and driven by what is really important for people and scientifically sound.”
During the 18 years of its existence, Pantarhei has filed more than 220 patents. Initially Pantarhei developed new medicines for Women’s Health. Following the foundation of the subsidiary company Pantarhei Oncology in 2014, the focus has been redirected to new treatment concepts for endocrine cancer, especially breast and prostate cancer.
Read more: Press Release New CEO Pantarhei Bioscience
Pantarhei Oncology announces favorable efficacy results of the fetal estrogen Estetrol in women with advanced breast cancer.
Pantarhei Oncology rapporteert positieve resultaten van de behandeling van borstkanker met het zwangerschapshormoon Estetrol.